Ann: Appendix 4D and Half Year Report to 30 June 2019, page-11

Unfortunately, IF they do find a new potentially worthwhile biotech, the whole merry go round starts again with (normally) a long lead time for approvals and commercialisation and the never ending need to tap shareholders for development / working capital.
Of course, with a new focus there will be new holders attracted by the shiny new bauble who will become believers and happy to fund (real life at this end of the market).
To try and balance my cynical comments - It is also true that it is worthwhile to try and turn this Company into a commercial enterprise to at least try and unlock the only asset it holds - which are the tax losses